What guidance did Core Laboratories's management provide for the next earnings period?

What were the key takeaways from Core Laboratories’s earnings call?

Did Core Laboratories beat or miss consensus estimates last quarter?

What is Core Laboratories's gross profit margin?

What does Core Laboratories do and what are its main business segments?

What were the key takeaways from Core Laboratories's earnings call?

What is the revenue and EPS growth rate for Core Laboratories year over year?

What is Core Laboratories's latest dividend and current dividend yield?

- **Revenue Growth**: Q4 2025 revenue up 7% Y/Y, driven by international demand and strong service segment performance.
- **Margin Expansion**: Reservoir Description operating margins improve to 14%, offsetting Production Enhancement margin contraction (7%).
- **Free Cash Flow Utilization**: $15.5M share buybacks in FY 2025, with continued opportunistic repurchases planned.
- **Tariff Mitigation**: Tariffs impacting margins by ~$0.02-0.03/Q, countered by regional supply chain adjustments.
- **Strategic Initiatives**: Expanding Middle East lab capabilities and monitoring unconventional opportunities in Algeria/Turkey.

**【CEO Summary Section】**
- Q4 2025 revenue increased 3% sequentially and 7% year-over-year, driven by strong international demand for proprietary technologies.
- Reservoir Description segment revenue grew 5% Q/Q and 6% Y/Y, with operating margins expanding to 14% (up 60bps sequentially).
- Production Enhancement revenue rose 8% Y/Y, though Q4 margins contracted to 7% due to a receivable provision and tariffs.
- FY 2025 free cash flow used for $15.5M share buybacks and dividend payments, with plans to continue opportunistic repurchases.

**【CFO Financial Commentary】**
- Q4 service revenue ($107M) up 6% Q/Q and 11% Y/Y, while product sales ($31.3M) declined 6% Q/Q and 4% Y/Y due to U.S. onshore activity decline.
- Cost of services efficiency improved to 75% of service revenue (vs. 76% prior year), though G&A expenses rose 9% Y/Y to $41.9M.
- EBIT ex-items ($15.7M) flat Y/Y, with net income ex-items ($9.7M) down 5% Q/Q and 7% Y/Y.
- Balance sheet: net debt reduced to $90.2M (leverage ratio 1.09x), with $22.8M cash on hand.

**【Q&A Highlights】**
- **Venezuela**: Core has legacy data and mobile lab capabilities to re-enter if operators return, but sees 2027+ potential.
- **Middle East**: Expanded lab in Saudi Arabia driving growth; Algeria/Turkey unconventional opportunities could require incremental CapEx.
- **Tariffs**: Impacting Production Enhancement margins by ~$0.02-0.03/Q, mitigated via regional sourcing shifts.
- **Cash Flow**: CFO prioritizes share buybacks (stock undervalued) alongside debt reduction, targeting 1.0x leverage ratio.

Core Laboratories Inc. (CLB) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue up 3% sequentially to $134.5 million, driven by international service demand.
- **Margin Expansion**: Operating margin improved to 12%, with EBIT up 15% YoY to $16.6 million.
- **Share Buybacks**: $5 million in share repurchases (1% of outstanding) alongside quarterly dividend.
- **Strategic Acquisitions**: Solintec acquisition structured with 50% earnout tied to 2026-2028 revenue targets.
- **International Growth**: Clients in Middle East, South Atlantic, and Asia Pacific report 2-3 year exploration and development plans.

**【Management Opening Remarks】**
- Q3 2025 revenue grew 3% sequentially to $134.5 million, driven by stronger international service demand in both Reservoir Description and Production Enhancement segments.
- Sequential operating margin improved to 12%, with EBIT of $16.6 million (+15% YoY).
- Company repurchased $5 million in shares (1% of outstanding) and maintained quarterly dividend, returning 100% of free cash flow to shareholders.

**【CEO Commentary】**
- **Reservoir Description**: Q3 revenue $88.2 million (+2% QoQ), operating margin 13%. Key projects include:
  - Phase 1 completion of Middle East reservoir fluid study using advanced PVT and microscopy technologies.
  - Ongoing phase 2 testing for pressure maintenance and solvent injection programs.
- **Production Enhancement**: Q3 revenue $46.3 million (+6% QoQ), operating margin 11%. Highlights:
  - Successful deployment of dual-end severing tool in West Africa to recover stuck drill pipe.
  - FLOWPROFILER EDS oil tracers used in Canada's heavy oil multilateral wells to optimize production profiles.
- Tariff impacts limited to 25% of product sales; 75% of revenue comes from untariffed services.

**【CFO Financial Commentary】**
- GAAP EPS $0.30 vs. Non-GAAP EPS $0.22 (ex-items basis).
- Free cash flow $6.5 million vs. $2 million in Q2, with full-year CapEx guidance $11-13 million.
- Balance sheet: Net debt $91.4 million (1.1x leverage), DSOs 71 days (improved from 75 days).
- 2025 tax rate maintained at 25%, with $42-44 million G&A expense guidance.

**【Q&A Highlights】**
- **M&A Strategy**: Solintec acquisition structured with 50% upfront payment and 50% earnout tied to 2026-2028 revenue targets. CEO noted this structure aligns seller incentives with long-term value creation.
- **International Outlook**: Clients in Middle East, South Atlantic margin, and Asia Pacific report 2-3 year growth plans for exploration, appraisal, and development activities. Core expects Reservoir Description to benefit most from this trend.
- **Tariff Mitigation**: 50% of product sales consumed domestically; R&D investments in U.S.-manufactured alternatives for imported steel components.


Core Laboratories Inc. (CLB) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue up 5% sequentially to $130.2M, driven by lab services recovery and international product sales.
- **Margin Expansion**: EBIT margin expanded 160bps to 11.1%, free cash flow up 43% to $10.4M.
- **Balance Sheet Strength**: Net debt reduced 9% to $94.8M, leverage ratio 1.27 (lowest in 8 years).
- **Strategic Wins**: HERO PerFRAC system wins Canada contract; thermal profiler tracers deployed in geothermal projects.
- **Guidance Caution**: Q3 revenue flat to +3%, reflecting geopolitical uncertainty and oil price volatility.

**【CEO Opening Remarks】**
- Q2 2025 revenue grew 5% sequentially to $130.2 million, driven by rebounding laboratory services and international product sales.
- Sequential improvements in operating income (+$2.7M), operating margins (11%), free cash flow ($10.4M), and EPS ($0.19).
- Share buybacks of 237,000 shares ($2.7M) and net debt reduction of $9M to $94.8M (leverage ratio 1.27, lowest in 8 years).
- Strategic focus on free cash flow generation, return on invested capital, and shareholder value through dividends and share repurchases.

**【CFO Financial Review】**
- Service revenue ($96.2M) up 1% sequentially, driven by recovery in laboratory assay services post-sanctions.
- Product sales ($33.9M) surged 19% sequentially, with 25% growth in international bulk orders.
- EBIT margin expanded 160bps to 11.1%, driven by manufacturing efficiencies and cost control.
- Net income ex-items ($8.8M) up 31% vs. Q1, but down 15% YoY due to lower U.S. onshore activity.
- Free cash flow yield improved, with 2025 CapEx forecast at $14-16M (2.5-4% of revenue).

**【Outlook & Guidance】**
- Q3 2025 revenue expected to range $127.5-134.5M, flat to up 3% vs. Q2.
- Reservoir Description: $84-88M revenue (flat) with $10.6-12.4M operating income.
- Production Enhancement: $43.5-46.5M revenue (+3-6%) with $2.9-3.7M operating income.
- EPS guidance $0.18-0.22, reflecting geopolitical uncertainty and oil price volatility.
- Tariffs expected to minimally impact services (75% of revenue) and 50% of product sales.

**【Operational Highlights】**
- **Reservoir Description:**
  - $86.3M revenue (+7% QoQ), 13% operating margin.
  - Colombia EOR project using PVT technology for CO2 sequestration validation.
  - Global lab network supports 1B bbl recoverable heavy oil in Eastern Llanos Basin.
- **Production Enhancement:**
  - $43.9M revenue (+3% QoQ), 9% operating margin.
  - HERO PerFRAC perforating system wins multi-operator Canada contract.
  - Thermal profiler tracers deployed in high-temperature geothermal projects.

**【Q&A Highlights】**
- **Proppant Design Innovation:**
  - Partnered with West Texas operator to test proppant particle size/sorting via tracer flowback analysis.
  - Demonstrated 15% improvement in fracture conductivity for new design.
- **Middle East Expansion:**
  - Unconventional lab opened in Dammam, Saudi Arabia, replicating North American frac tech.
  - Formation damage testing investments to address completion fluid-rock interactions.
  - Active discussions for thermal profiler tracer deployments in geothermal projects.


Core Laboratories Inc. (CLB) Q2 2025 Earnings Call Transcript

- **Revenue Challenges:** Q1 2025 revenue down 4% to $123.6M due to sanctions and seasonal decline, with RD (-7%) and PE (flat) segments under pressure.
- **Cost Management:** Net debt reduced by $5M to $103.9M; $2M share buybacks and dividend payments maintained despite headwinds.
- **Profit Outlook:** Q2 operating margin expected at 11%, with potential H2 improvement from cost reductions and international project recoveries.
- **Geopolitical Risks:** Middle East and Africa projects resilient, but Mexico and Colombia face challenges; Brazil shows gradual growth potential.
- **Cash Flow Focus:** Free cash flow of $3.9M in Q1; CapEx guidance of $14-16M for 2025.

**【CEO Opening Remarks】**
- Q1 2025 revenue decreased 4% sequentially to $123.6M, driven by seasonal decline and expanded sanctions in Eastern Europe.
- Reservoir Description (RD) revenue down 7% QoQ due to geopolitical volatility, while Production Enhancement (PE) revenue remained flat.
- Operating margins in RD and PE were 10% and 8% respectively, impacted by high decremental costs from lost revenue.
- Net debt reduced by $5M to $103.9M, with leverage ratio at 1.31, lowest in 8 years.
- Share buybacks of $2M (132,000 shares) and dividend payments continued, with focus on deleveraging.

**【CFO Financial Review】**
- GAAP net loss of $0.2M vs. $10.4M operating income ex-items, due to $3.5M non-cash stock comp and $3.4M restructuring costs.
- Service revenue ($95.1M) down 1% QoQ, with U.S. diagnostic services growth offsetting international assay declines.
- Product sales ($28.5M) down 13% QoQ, impacted by $1.1M delayed international orders.
- G&A expenses stable at $10.1M, with 2025 guidance of $40-42M.
- Free cash flow of $3.9M after $2.8M CapEx, with full-year CapEx guidance of $14-16M.

**【Segment Performance】**
- **Reservoir Description:**
  - Q1 revenue $80.9M (-7% QoQ), operating income $7.8M (10% margin).
  - Libya workshop highlights new opportunities in Africa; Middle East and Asia projects resilient.
  - Gulf of Mexico completions delayed by hurricanes resumed in Q1.
- **Production Enhancement:**
  - Q1 revenue $42.7M (flat QoQ), operating income $3.4M (8% margin).
  - HERO-HardRock PerFRAC success in international abandonment project.
  - SPECTRASTIM tracer adoption saves $2M on Gulf of Mexico well.

**【Q&A Highlights】**
- **Profit Margin Outlook:**
  - Q2 operating margin ~11% (vs. 10% Q1), with potential improvement in H2 from cost reductions.
  - PE margin contraction in Q2 due to mix shift from high-margin diagnostics to product sales.
- **Geopolitical Risks:**
  - Mexico market challenges persist; Middle East and Africa projects remain resilient.
  - Colombia political instability may impact activity; Brazil gradual improvement expected.
- **Cash Flow Strategy:**
  - Free cash flow prioritized for debt reduction; $132K shares repurchased in Q1.
  - No immediate plans for special dividends, focusing on balance sheet strength.


Core Laboratories Inc. (CLB) Q1 2025 Earnings Call Transcript

- **Debt Reduction Success**: Net debt down 28% in 2024, leverage ratio 1.31 (lowest in 8 years).
- **Free Cash Flow Surge**: Full-year free cash flow $43.4M (vs $14.2M in 2023).
- **Geopolitical Risks**: Q1 2025 sanctions caused $1M+ revenue loss in Eastern Europe and lab services.
- **International Growth**: Mid-single-digit Reservoir Description expansion driven by South Atlantic, Middle East, and Asia-Pacific projects.

**【CEO Opening Remarks】**
- Q4 2024 revenue down 4% sequentially to $129.2M, but full-year revenue up 3% to $523.8M.
- Full-year operating income up 7% to $65.3M, EPS up 9% to $0.87.
- Net debt reduced by $42M in 2024, leverage ratio down to 1.31 (lowest in 8 years).
- 2025 focus: international growth, US onshore flat/down, Aberdeen facility rebuild ($10-12M capex).

**【CFO Financial Review】**
- Q4 GAAP net income $7.4M, Non-GAAP EPS $0.22 (down 12% vs Q3).
- Free cash flow $16.2M in Q4, full-year $43.4M (vs $14.2M in 2023).
- Reservoir Description margins 16% (down 110bps Q/Q), Production Enhancement margins 4%.
- 2025 tax rate expected at 25% (vs 20% in 2024).

**【Segment Performance】**
- **Reservoir Description**: Q4 revenue $86.8M (-2% Q/Q), operating income $14.1M. Headwinds from US onshore decline and geopolitical sanctions in Russia/Ukraine/Middle East.
- **Production Enhancement**: Q4 revenue $42.4M (-7% Q/Q), operating income $1.5M. US onshore completion activity down, but international product sales up 8% Y/Y.

**【Q&A Highlights】**
- **Competitive Pricing**: US Production Enhancement market crowded, stable pricing but limited upside.
- **Geopolitical Impact**: Q1 2025 sanctions reduced product sales to Eastern Europe and crude assay lab work.
- **Weather Impact**: Gulf Coast freezes cost ~$1M in Q1 revenue, but high incremental margins.
- **International Growth**: South Atlantic margin, Middle East, Norway, and Asia-Pacific projects driving mid-single-digit Reservoir Description growth.


Actual											0.31	0.14	0.16	0.18	0.15	0.18	0.18	0.2	0.08	0.12	0.18	0.2	0.19	0.21	0.22	0.19	0.19	0.22	0.25	0.22	0.14	0.19	0.22	0.21
Forecast											0.3216	0.1093	0.1445	0.1533	0.1306	0.1911	0.1867	0.201	0.0667	0.1369	0.1523	0.1938	0.1597	0.2039	0.2195	0.1881	0.1571	0.1958	0.2439	0.2193	0.1443	0.1864	0.1943	0.1912
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.61%	+28.09%	+10.73%	+17.42%	+14.85%	-5.81%	-3.59%	-0.50%	+19.94%	-12.34%	+18.19%	+3.20%	+18.97%	+2.99%	+0.23%	+1.01%	+20.94%	+12.36%	+2.50%	+0.32%	-2.98%	+1.93%	+13.23%	+9.83%

Actual	--	--	--	--	--	--	--	--	--	--	152.40M	115.74M	105.38M	113.75M	108.40M	118.75M	117.98M	125.14M	115.30M	120.90M	125.97M	127.57M	128.36M	127.88M	125.34M	128.21M	129.64M	130.58M	134.40M	129.24M	123.58M	130.16M	134.52M	138.25M
Forecast	--	--	--	--	--	--	--	--	--	--	152.37M	115.91M	109.76M	109.19M	110.51M	119.53M	122.68M	122.42M	113.01M	121.46M	126.08M	130.03M	126.18M	131.25M	129.81M	128.00M	124.13M	132.85M	134.16M	132.18M	124.38M	129.13M	131.22M	132.13M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.02%	-0.15%	-3.99%	+4.17%	-1.91%	-0.65%	-3.83%	+2.22%	+2.02%	-0.46%	-0.09%	-1.89%	+1.72%	-2.57%	-3.44%	+0.17%	+4.44%	-1.71%	+0.18%	-2.23%	-0.64%	+0.80%	+2.51%	+4.63%

CLB

CLB fundamentals

CLB Q4 2025 Earnings

Earnings Call

You can ask Aime

CLB

CLB fundamentals

CLB Q4 2025 Earnings

Earnings Call

CLB Earnings Call Summary for Q4/20258:30 AM on Feb 5, 2026

CLB Earnings Call Summary for Q3/20258:30 AM on Oct 23, 2025

CLB Earnings Call Summary for Q2/20258:30 AM on Jul 24, 2025

CLB Earnings Call Summary for Q1/20258:30 AM on Apr 24, 2025

CLB Earnings Call Summary for Q4/20248:30 AM on Jan 30, 2025

You can ask Aime